Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer (RADAR II E)

AstraZeneca

Status: Completed

Conditions: Breast Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT00692289

NIS-OHU-ARI-2007/1

Details and patient eligibility

About

This is an open label, non-interventional quality of life analysis for Arimidex treated postmenopausal patients in early breast cancer by investigator's questionnaire

Enrollment: 1,510 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provision of informed consent
• Postmenopausal, hormon receptor positive patients with early breast cancer treated with Arimidex
• Investigators are requested to recruit patients only with at least 1 month prior Arimidex treatment.

Exclusion criteria

• Allergy to substance of medication
• Pre-perimenopausal woman
• Woman not eligible for treatment